Long Position on LCI @ $65.40 on 3/16/2015 (Momentum)

Lannett Company, Inc. (LCI) develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States.

It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas.

The company provides its products for various medical indications comprising glaucoma, migraine, antibiotic, pain management, anesthetic, endometriosis, anxiety, irritable bowel syndrome, obesity, congestive heart failure, antipsychotic, tuberculosis, thyroid deficiency, dryness of the mouth, epilepsy, gout, low sodium, bronchospasms, hypertension, and gallstone, as well as HIV.

It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Valium, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Dilaudid, Niazid, Levoxyl, Synthroid, Loxitane, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, Actigall, and Retrovir brands.

The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations.

Shares have formed a bullish "cup & handle" and higher share prices are expected for this stock.

52-Week Trading Range: $29.12 - $66.90

Entry Point: $65.40

Stop Loss: $62.13

Target Price: $71.94

Updates

4/20/2015 10:54:52 AM

We are closing LCI at $65.65 after its 30 days expired.

Position closed on 4/20/2015 at price of $65.65 with a 0.38% gain in 35 days.

Back to Portfolio